Back

START (COG0203)

Official Title

Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Study Details

The purpose of the START study is to test a study drug to see if it may potentially be used to treat people with early Alzheimer's Disease.

Principal Investigator

Dr. Joy Snider

IRB Number

202306051

Eligibility

1. Participants must be 50-85 years old
2. Participants must have either mild cognitive impairment due to Alzheimer's or dementia, OR memory concerns (a diagnosis is not necessary to qualify for the study)

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back